Cambridge, UK, 28 Sept 2021: o2h Ventures is pleased to announce an investment into Sanome, a London-based biotech company combining biomarkers (health data points) into a human health passport that helps people understand and manage their health better. Sanome raised £2m as its first round of funding from a number of leading UK and European HealthTech specialist investors including o2h Ventures.
Sanome is a digital health company that has developed a diagnostics innovation engine that combines biomarkers to produce medical-grade, at-home diagnostic products (IVDs) more efficiently and effectively. Most digital health, wearables, and consumer biotech tools have limited medical use because it’s hard to validate them clinically. Sanome’s novel approach leverages these existing technologies to develop an at-home test that is clinically validated to improve patient outcomes and reduce healthcare costs, ultimately laying the foundation for the early detection and prevention of diseases of high unmet need.
This is o2h Ventures’ second investment from the recently launched human health SEIS fund which aims to invest in seed-stage SEIS qualifying companies covering novel drug discovery, enabling services and AI technologies.
The investment will be used to expand the team across London, Amsterdam, and Cambridge; deliver on key strategic and commercial partnerships to develop and validate the first set of IVD candidates.
Benedikt von Thüngen, CEO and co-founder of Sanome, commented: “Working with o2h Ventures will aid Sanome in accelerating its journey into disrupting the healthcare landscape, to enable an inclusive approach to disease detection and management via home health tools. We are thrilled to have their support for an exciting journey ahead.”
Sunil Shah, CEO and Co-founder of o2h Ventures, said: “The datasets and patient information that is collected by Sanome will be a valuable asset when collaborating with big pharma. The data will help create more effective medicines and enable faster patient recruitment for clinical trials.”
Sanome was founded by experienced entrepreneurs Benedikt von Thüngen (CEO) and Dr Marc van der Schee (Chief Medical Officer). They combine unique experiences, including software, clinical, healthcare, AI/ ML, and biomarker development, and have built and scaled multiple successful companies before, including Owlstone Medical and Speechmatics.
Sanome is combining different types of biomarkers to develop engaging, useful and accurate diagnostic products (IVDs) that enable early detection and prevention of disease. The IVD innovation engine will ultimately enable new approaches for healthcare delivery, providing access to novel at-home testing paradigms for all people.
For more information, please see – https://www.sanome.com/
About o2h Ventures
The o2h Ventures ‘Human Health’ funds make tax-efficient EIS and SEIS investments in Pre-Seed and Seed stage companies that address human disease: we fund the development of novel therapeutic treatments; we help build new services and tools offerings throughout the biotech ecosystem, and we spur the creation of software & artificial intelligence that will change healthcare.
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.
For more information or to invest in the fund, please visit www.o2hventures.com
Marketing Manager, o2h Ventures